Novosanis Closes B Round of Financing
News Oct 01, 2015
Novosanis closed a new round of financing. The share capital was increased by a combined cash contribution from current investor Taste Invest and from the Novosanis management team.
Novosanis is a Flemish medical device company active in the field of infectious diseases and oncology. The company aims at detection, prevention and treatment of sexually transmitted infections and cancer. Novosanis was founded in 2013.
“It is clear that medical devices and diagnostics will play an increasingly important role in health care at an international level. The additional funding for Novosanis provided by Taste Invest underlines our belief in the growth of the company and its devices. Also, the contribution by the Novosanis management team further highlights the trust in the global expansion of the company.” says Philip De Mulder, CEO Taste Invest nv.
Koen Beyers, CTO Novosanis, says “Novosanis has made significant progress both at the level of R&D as at the level of production capabilities and sales. Since the foundation of Novosanis early 2013, our multidisciplinary team has now grown to 9 people. The round A series of funding combined with subsidies from IWT (Agency for Innovation through Science and Technology) has led to the CE-IVD label and commercial launch of our first device (Colli-Pee™), which is backed by a successful proof-of-concept study. Also, the device is enrolled in several clinical trials on detection of infectious diseases as well as biomarkers for cancer in urine.”
“Importantly, first commercial sales of the Colli-Pee™ device have been realized. Therefore, the new funding round is needed to enable further development and commercialization of the VAX-ID™ device platform suited for accurate injections in the dermal layer of the skin. We are currently organizing several proof-of-concept studies throughout Europe and we expect obtaining the CE-label early 2016.” explains Vanessa Vankerckhoven, CEO Novosanis.
Novosanis currently has two device (platforms) in its portfolio: VAX-ID™, suited for accurate injection of e.g. vaccines and biologicals in the dermal layer of the skin and Colli-Pee™, suited for standardized collection of first void urine allowing detection of sexually transmitted infections, including human papilloma virus able to cause cervical cancer and cancer biomarkers for early detection of e.g. prostate cancer.
Scientists have identified sodium glucose transporter 2 (SGLT2) as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes tumor growth. The finding provides evidence that SGLT2 may be a novel biomarker that scientists can use to help diagnose precancerous lung lesions and early-stage lung cancers.READ MORE